

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 July 2025 (31.07.2025)



(10) International Publication Number
WO 2025/160452 A1

- (51) **International Patent Classification:**
C12N 15/86 (2006.01) *A61K 48/00* (2006.01)
- (21) **International Application Number:**
PCT/US2025/013023
- (22) **International Filing Date:**
24 January 2025 (24.01.2025)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/625,206 25 January 2024 (25.01.2024) US
- (71) **Applicants:** **GENZYME CORPORATION** [US/US];
450 Water Street, Cambridge, Massachusetts 02141 (US).
SUNNYBROOK RESEARCH INSTITUTE [CA/CA];
2075 Bayview Avenue, Toronto, Ontario M4N 3M5 (CA).
- (72) **Inventors:** **AUBERT, Isabelle**; 2075 Bayview Avenue,
Toronto, Ontario M4N 3M5 (CA). **ELMER, Bradford Miller**;
c/o Sanofi, Patent Department, 450 Water Street, Cambridge,
Massachusetts 02141 (US). **HYNENEN, Kullervo**;
2075 Bayview Avenue, Toronto, Ontario M4N 3M5 (CA).
KOFOED, Rikke H.; 2075 Bayview Avenue, Toronto, Ontario
M4N 3M5 (CA). **MUELLER,**

Christian; c/o Sanofi, Patent Department, 450 Water Street,
Cambridge, Massachusetts 02141 (US).

(74) **Agent:** **SNYDER, Seth et al.**; Morrison & Foerster LLP,
425 Market Street, San Francisco, California 94105 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) **Title:** METHODS FOR FUS-BASED DELIVERY OF VIRAL PARTICLES TO THE BRAIN




FIG. 1C

(57) **Abstract:** Provided herein are methods to treat various neurodegenerative disorders comprising delivering a viral particles to the whole brain, including both superficial and deep structures. In some aspects, the viral particles are administered at low dose levels to the CSF, in conjunction with microbubbles followed by application of focused ultrasound (FUS) to a region of interest of the brain, thereby causing entry of the viral particles to the brain.

[Continued on next page]

WO 2025/160452 A1

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*